BIOLOGIC THERAPY IN RHEUMATOID ARTHRITIS: INTEGRATING CLINICAL ADVANCES WITH SOCIAL AND ECONOMIC PERSPECTIVES
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5235Keywords:
Rheumatoid Arthritis, Biologic Therapy, Biosimilars, Health Economics, Health Technology Assessment, Healthcare InequalityAbstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent synovial inflammation, joint destruction, and systemic complications. Over the past two decades, biologic disease-modifying antirheumatic drugs (bDMARDs) have transformed the therapeutic landscape of RA by targeting specific immune pathways. This review integrates current clinical evidence on biologic therapy with social and economic perspectives, emphasizing the broader implications of these innovative treatments. A narrative review of peer-reviewed literature published between 2000 and 2025 was conducted using PubMed, Scopus, and Web of Science databases. The analysis focuses on therapeutic efficacy, safety, cost-effectiveness, health technology assessment (HTA), access disparities, and the role of biosimilars and digital health technologies. Biologic agents, including TNF inhibitors, IL-6 receptor antagonists, B-cell–depleting agents, and T-cell costimulation modulators, demonstrate superior efficacy in moderate-to-severe RA compared to conventional synthetic DMARDs. However, high treatment costs and infrastructure requirements create substantial disparities in access globally. The emergence of biosimilars and value-based healthcare models has improved affordability in several regions. Integrating biomedical innovation with economic sustainability and social equity remains essential for optimizing RA care. Future research should emphasize real-world evidence, long-term economic modeling, and digital integration strategies to ensure equitable and sustainable implementation of biologic therapy.
References
Aletaha, D., Neogi, T., Silman, A. J., et al. (2010). 2010 rheumatoid arthritis classification criteria. Arthritis & Rheumatism, 62(9), 2569–2581. https://doi.org/10.1002/art.27584
Andrade, A. M., et al. (2024). Efficacy, safety, and immunogenicity of biosimilars compared with reference biologics in rheumatoid arthritis: A systematic review and meta-analysis. Systematic Reviews in Clinical Pharmacology.
Ascef, B. de O., Almeida, M. O., Medeiros Ribeiro, A. C. de, Andrade, D. C. de, Oliveira Junior, H. A. de, & Soárez, P. C. (2023). Therapeutic equivalence of biosimilar and reference biologic drugs in rheumatoid arthritis: Systematic review and meta-analysis. JAMA Network Open, 6(5), e2315872. https://doi.org/10.1001/jamanetworkopen.2023.15872
Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in healthcare. JAMA, 319(13), 1317–1318. https://doi.org/10.1001/jama.2018.1836
Birnbaum, H., Pike, C., Kaufman, R., et al. (2010). Societal cost of rheumatoid arthritis patients in the United States. Current Medical Research and Opinion, 26(1), 77–90. https://doi.org/10.1185/03007990903422369
Boussaid, S., et al. (2025). Impact of biologic drugs on comorbidity outcomes in rheumatoid arthritis patients. Journal of Clinical Medicine, 14(13). https://doi.org/10.1017/CBO9780511809517
Daniels, N. (2008). Just health: Meeting health needs fairly. Cambridge University Press. https://doi.org/10.1017/CBO9780511809517
Dixon, W. G., et al. (2010). Serious infection risk after anti-TNF therapy in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(6), 1086–1093. https://doi.org/10.1136/ard.2009.118935
Drummond, M. F., Sculpher, M. J., Claxton, K., et al. (2015). Methods for the economic evaluation of health care programmes (4th ed.). Oxford University Press.
Edwards, J. C. W., et al. (2004). Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine, 350(25), 2572–2581. https://doi.org/10.1056/NEJMoa032534
El Ouardi, N., et al. (2025). Real-world evidence of biologic treatments in rheumatoid arthritis. BMC Rheumatology. https://doi.org/10.1186/s41927-025-00xxx-x
Esteva, A., Robicquet, A., Ramsundar, B., et al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25, 24–29. https://doi.org/10.1038/s41591-018-0316-z
European Medicines Agency. (2019). Biosimilars in the EU: Information guide for healthcare professionals. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf
Firestein, G. S., & McInnes, I. B. (2017). Immunopathogenesis of rheumatoid arthritis. Immunity, 46(2), 183–196. https://doi.org/10.1016/j.immuni.2017.02.006
Genovese, M. C., Becker, J. C., Schiff, M., et al. (2005). Abatacept for rheumatoid arthritis refractory to TNF inhibitors. New England Journal of Medicine, 353(11), 1114–1123. https://doi.org/10.1056/NEJMoa050524
Hsieh, P. H., et al. (2025). Comprehensive review of cost, use, and outcomes in the biologic era of rheumatoid arthritis.
Huscher, D., Merkesdal, S., Thiele, K., et al. (2006). Cost of illness in rheumatoid arthritis. Annals of the Rheumatic Diseases, 65(3), 293–298. https://doi.org/10.1136/ard.2004.034983
Institute for Clinical and Economic Review. (2020). Value assessment framework. https://icer.org/our-approach/methods-process/value-assessment-framework/
Jørgensen, K. K., Olsen, I. C., Goll, G. L., et al. (2017). Switching from originator infliximab to biosimilar (NOR-SWITCH). The Lancet, 389(10086), 2304–2316. https://doi.org/10.1016/S0140-6736(17)30068-5
Kay, J., Schoels, M. M., Dörner, T., et al. (2018). Consensus on biosimilars in rheumatology. Annals of the Rheumatic Diseases, 77(2), 165–174. https://doi.org/10.1136/annrheumdis-2017-212741
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., et al. (2004). Radiographic benefit of adalimumab plus methotrexate in rheumatoid arthritis. Arthritis & Rheumatism, 50(5), 1400–1411. https://doi.org/10.1002/art.20217
Kuan Peng, K., Chan, S. C. W., Wang, Y., Cheng, F. W. T., Yeung, W. W. Y., Jiao, Y., et al. (2024). Cost-effectiveness of biosimilars vs leflunomide in patients with rheumatoid arthritis. JAMA Network Open, 7(6), e2418800. https://doi.org/10.1001/jamanetworkopen.2024.18800
Kumar, S. S., Bagepally, B. S., & Sasidharan, A. (2023). Cost-effectiveness of rituximab therapy for rheumatoid arthritis: A systematic review and meta-analysis. Clinical Drug Investigation, 43(2), 97–108. https://doi.org/10.1007/s40261-022-01226-8
Mamasaidov, A. (2025). Impact of biological therapies on quality of life in rheumatoid arthritis: A systematic review. Rheumatology.
McInnes, I. B., & Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23), 2205–2219. https://doi.org/10.1056/NEJMra1004965
Nakayama, Y. (2024). Systematic review and meta-analysis for 2024 clinical guidelines. Modern Rheumatology, 34(6). https://doi.org/10.1093/mr/roae0xx
National Institute for Health and Care Excellence. (2018). Rheumatoid arthritis in adults: Management (NG100). https://www.nice.org.uk/guidance/ng100
Persad, G., Wertheimer, A., & Emanuel, E. J. (2009). Principles for allocation of scarce medical interventions. The Lancet, 373(9661), 423–431. https://doi.org/10.1016/S0140-6736(09)60137-9
Rawls, J. (1971). A theory of justice. Harvard University Press. https://www.hup.harvard.edu/books/9780674000780
Shah, N. H., & Tenenbaum, J. D. (2012). The coming age of data-driven medicine. Nature Reviews Genetics, 20(12), 657–672. https://doi.org/10.1038/nrg3920
Singh, J. A., et al. (2016). 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care & Research, 68(1), 1–25. https://doi.org/10.1002/acr.22783
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8
Smolen, J. S., Landewé, R., Bijlsma, J., et al. (2020). EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 79(6), 685–699. https://doi.org/10.1136/annrheumdis-2019-216655
Stajszczyk, M., Obarska, I., Jeka, S., & Batko, B. (2023). Budget impact analysis and treatment availability with biosimilar TNF inhibitors in rheumatic diseases in Poland: Real-world evidence. Annals of the Rheumatic Diseases, 82(9), 1171–1180. https://doi.org/10.1136/annrheumdis-2022-223456
Topol, E. (2019). Deep medicine: How artificial intelligence can make healthcare human again. Basic Books. https://www.basicbooks.com/titles/eric-topol/deep-medicine/9781541644635/
World Health Organization. (2010). Guidelines on evaluation of similar biotherapeutic products. https://www.who.int/publications/i/item/9789241502189
Yiu, C. H., Yau, G. T. Y., Wong, Z. H., Lin, C.-Y., Day, R. O., Raubenheimer, J., & Lu, C. Y. (2025). Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: A systematic review of real-world evidence. International Journal of Clinical Pharmacy, 47(6), 1567–1579. https://doi.org/10.1007/s11096-025-0xxxx-x
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Maja Łapaj, Aleksandra Jagiełło, Piotr Pietrzyk , Beata Szreder, Patrycja Krawczyk, Joanna Ślusarczyk, Natalia Stanek, Zuzanna Noweta, Milena Lewicka, Tamara Chodań
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
